Prevention of COVID-19 with booster-dose strategy among healthy adults who recieved 2-dose of CoronaVac using ChAdOx1 nCoV-19 (AZD1222) vaccine COVID-19 Vaccine, AstraZeneca Booster, Intradermal
Conditions
Interventions
The participant will recieve a booster dose of 0.1 ml intradermal ChAdOx1 nCov19 1222 at the day of enrollment in the study
Prevention
AZD1222 Boster Dose 0.1 mL Intradermal
Sponsors
Ratchadaphisek Sompoch Research Fund
Eligibility
Sex/Gender
All
Age
18 Years to 59 Years
Inclusion criteria
Inclusion criteria: 1.Thai, age 18-59, 2.Have a history of reciving two dose of CoronaVac vaccine with 14-35 days apart, 3.Post-second dose of CoronaVac vaccine for more than 60-180 days on day of participation in the study.
Exclusion criteria
Exclusion criteria: 1.Have a history of COVID-19 infection, 2.Recieved immunosuppressants within 3 months prior to participant in the study, 3.Recieved blood or blood products within 3 months prior to participant in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Breakthrough infection during 6 months post booster 6 months post booster Rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Reactogenicity and adverses events Day1, Day14 Prevalence,Anti-S-RBD Antibody level Day0, Day14, Day90 or Day180 BIOTEC COVID-19 IgG ELISA ,sVNT for neutralizing antibody Day0, Day14, Day90 or Day180 ELISA,T and B cell response Day0, Day14, Day90 or Day180 ELISPOT assay (Mabtech) | — |
Countries
Thailand
Contacts
Public ContactThanyawee Puthanakit
Department of Pediatrics , Faculty of Medicine
Outcome results
None listed